Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
QSI 
QuantumSi Inc (QSI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/12/2025: QSI (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $2.67
1 Year Target Price $2.67
| 1 | Strong Buy |
| 1 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -67.8% | Avg. Invested days 23 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/12/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 238.94M USD | Price to earnings Ratio - | 1Y Target Price 2.67 |
Price to earnings Ratio - | 1Y Target Price 2.67 | ||
Volume (30-day avg) 3 | Beta 2.87 | 52 Weeks Range 0.61 - 5.77 | Updated Date 09/14/2025 |
52 Weeks Range 0.61 - 5.77 | Updated Date 09/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.67 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -4527.58% |
Management Effectiveness
Return on Assets (TTM) -27.01% | Return on Equity (TTM) -46.87% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 35875333 | Price to Sales(TTM) 70.03 |
Enterprise Value 35875333 | Price to Sales(TTM) 70.03 | ||
Enterprise Value to Revenue 10.51 | Enterprise Value to EBITDA 0.63 | Shares Outstanding 182558000 | Shares Floating 165746369 |
Shares Outstanding 182558000 | Shares Floating 165746369 | ||
Percent Insiders 12.49 | Percent Institutions 32.44 |
Upturn AI SWOT
QuantumSi Inc
Company Overview
History and Background
QuantumSi was founded in 2013. It has focused on developing its next-generation single-molecule protein sequencing platform. The company went public via a SPAC merger in 2021.
Core Business Areas
- Protein Sequencing: Development and commercialization of a single-molecule protein sequencing platform aimed at providing researchers and clinicians with tools for proteomics research and diagnostics.
Leadership and Structure
John Stark is the CEO. The company has a board of directors comprised of industry experts and venture capitalists.
Top Products and Market Share
Key Offerings
- Platinum: QuantumSi's flagship protein sequencing instrument. It provides single-molecule sensitivity, high throughput, and low cost for protein analysis. Market share is still developing. Competitors include Bruker (BRKR) and Pacific Biosciences (PACB) in proteomics research.
- Consumables: Specific reagent kits and microfluidic chips designed for use with the Platinum instrument. Revenue figures are not publicly available, however, depend on the use of the Platinum instrument. Competitors include other proteomics reagent and consumables suppliers.
Market Dynamics
Industry Overview
The proteomics market is expanding rapidly due to advances in technology and increasing demand for personalized medicine. The market is highly competitive, with many established players and emerging startups.
Positioning
QuantumSi aims to disrupt the proteomics market with its unique single-molecule sequencing approach. It hopes to offer advantages in terms of speed, sensitivity, and cost compared to existing technologies.
Total Addressable Market (TAM)
The proteomics market is estimated to be in the tens of billions of dollars. QuantumSi aims to capture a significant portion of this TAM through its innovative platform.
Upturn SWOT Analysis
Strengths
- Novel single-molecule protein sequencing technology
- Potential for high throughput and low cost
- Experienced leadership team
- Strong IP position
Weaknesses
- Relatively new company with limited commercial track record
- Requires high capital expenditure
- High cash burn
- Negative Earnings
Opportunities
- Growing proteomics market
- Increasing demand for personalized medicine
- Potential for partnerships with pharmaceutical companies
- Expansion into new applications, such as drug discovery
Threats
- Competition from established proteomics companies
- Technological advancements by competitors
- Regulatory hurdles
- Economic downturn
Competitors and Market Share
Key Competitors
- BRKR
- PACB
- ILMN
Competitive Landscape
QuantumSi is a relatively small player in the proteomics market, facing competition from established companies with greater resources and market share. QuantumSi differentiates itself with its single-molecule sequencing platform.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is limited due to the early stage of the company.
Future Projections: Future growth depends on the successful commercialization of the Platinum instrument and expansion into new markets.
Recent Initiatives: Recent initiatives include new product launches, partnerships, and expansion of the sales and marketing team.
Summary
QuantumSi is a developing company with promising technology, though not yet profitable. The company is focused on disrupting the proteomics market with single-molecule sequencing. Its high cash burn and competition from established companies are key challenges. Successfully navigating commercialization and securing partnerships are crucial for the company's success.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Market share figures are estimates and may not be precise. The proteomics market is a fast-evolving field.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About QuantumSi Inc
Exchange NASDAQ | Headquaters Branford, CT, United States | ||
IPO Launch date 2021-06-10 | President, CEO & Director Mr. Jeffrey Alan Hawkins | ||
Sector Healthcare | Industry Medical Devices | Full time employees 149 | Website https://www.quantum-si.com |
Full time employees 149 | Website https://www.quantum-si.com | ||
Quantum-Si incorporated, a life sciences company, engages in the development of single-molecule detection platform to enable Next Generation Protein Sequencing (NGPS). The company offers Platinum NGPS instrument that provides single molecule amino acid level resolution with a streamlined workflow, including automated data analysis that accessible to researchers in all laboratory types; Platinum Pro NGPS instrument, a single molecule amino acid resolution, which provides an enhanced user interface, cloud or on instrument data analysis and an available pro mode; Library preparation kits to prepare protein sample for sequencing; Barcoding Kits to optimize the workflow and performance of technology; and Sequencing Kits contains the reagents and consumables used to perform NGPS on the Platinum or Platinum Pro instrument. It also provides Platinum Analysis Software, a cloud-based solution that automates data analysis workflows and provides a user-friendly interface and visualization of the sequencing results. Its products are used in antibody characterization, biomarker identification, protein identification, protein variants, protein barcoding, and post translational modification analysis applications. Quantum-Si incorporated was founded in 2013 is headquartered in Branford, Connecticut.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.